| 词条 | OyaGen |
| 释义 |
| name = OyaGen, Inc. | logo = OyaGen logo.jpg | logo_caption = Therapeutics Targeting Editing Enzymes | image = | image_caption = | type = Private | industry = {{ubl|Biotechnology|Pharmaceutical research}} | foundation = Rochester, New York 2003 | founder = Dr. Harold Smith | location_city = Rochester, New York | location_country = US | locations = | area_served = Global | key_people = {{ubl|Dr. Harold Smith, CEO and President|Thomas Fitzgerald, COO|Dr. Ryan Bennett, CSO}} | products = Antiviral therapeutic lead compounds | services = {{ubl|Assay development|Lead compound optimization}} | owner = | num_employees = 6 | homepage = {{URL|oyageninc.com}} }}OyaGen is a Rochester, New York-based startup company that is focused on developing treatments for HIV. The company was founded in 2003 by Dr. Harold Smith, a professor of biochemistry and biophysics at the University of Rochester.[1][2] OyaGen was founded on research conducted by Dr. Smith and Dr. Hui Zang, an HIV researcher at Thomas Jefferson University.[1] ResearchOyaGen's research has focused on developing drug-based treatments for HIV and the company has three lead HIV drugs based upon editing enzymes in preclinical development.[3] The company is exploring ways to prevent HIV from disabling the production of APOBEC3G (A3G), a naturally occurring editing enzyme that stops HIV from replicating.[1] A3G combats HIV infection by interacting with and mutating the virus' RNA.[3][4] The mutations genetically damage the virus protein and render HIV unable to replicate which halts the spread of the virus.[3][4] In laboratory testing, OyaGen was able to use drug therapy to shield A3G from HIV, which allowed A3G to function normally and halt the spread of the virus.[5] The company is also researching drugs that protect A3G from Viral infectivity factor (ViF).[4][6] ViF is a protein created by HIV that "tricks" the body into destroying A3G by binding to it.[4][6] Interfering with ViF's ability to bind to A3G can effectively block HIV replication.[7] OyaGen is researching several compounds that prevent ViF from disabling A3G, including A3G agonists, ViF destabilizers and ViF dimerization antagonists.[7][8] FundingThe company received seed funding from Trillium Group's University Technology Fund and the University of Rochester Medical Center.[1][5] It has also received funding from the New York State Retirement Common Fund's Private Equity Program.[9][10] The New York State Retirement Common Fund has invested approximately $1.4 million in the company since 2006.[10] OyaGen's research has also been underwritten in part by the National Institutes of Health, which awarded grants to the company in 2011,[11] 2012,[12] and 2013.[13] See also
References1. ^1 2 3 {{cite news|title=UR Invests in Anti-HIV Startup|author=Michael Wentzel|work=Rochester Chronicle|date=12 January 2004}} 2. ^{{cite web|url=http://www.rbj.net/article.asp?aID=201030|title=Henrietta firm OyaGen receives $150,000 investment|author=Thomas Adams|work=Rochester Business Journal|date=16 September 2013|accessdate=1 June 2014}} 3. ^1 2 {{cite web|url=http://www.genengnews.com/gen-articles/hiv-researchers-seek-a-potential-cure/4997/|title=HIV Researchers Seek a Potential Cure|author=Gail Dutton|work=Genetic Engineering & Biotechnology News|date=1 October 2013|accessdate=1 June 2014}} 4. ^1 2 3 {{cite journal|url=http://www.retrovirology.com/content/4/1/81|title=The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G|author1=James H Miller|author2=Vlad Presnyak|author3=Harold C Smith|department=Department of Biochemistry and Biophysics, 601 Elmwood Ave, Rochester, NY 14642, USA|work=Retrovirology|volume=4|date=27 July 2007|publication-date=24 November 2007|doi=10.1186/1742-4690-4-81|accessdate=1 June 2014|pmid=18036235|pmc=2222665|page=81|issue=1}} 5. ^1 {{cite web|url=http://www.democratandchronicle.com/article/20100402/BUSINESS/4020315/|title=Will health reform be shot in arm for biotech firms?|author=Tom Tobin|work=Rochester Democrat & Chronicle|date=2 April 2010|accessdate=1 June 2014}} 6. ^1 {{cite web|url=http://roc.democratandchronicle.com/article/20050901/BUSINESS/509010363/OyaGen-blazing-path-toward-anti-AIDS-drug|title=OyaGen blazing path toward anti-AIDS drug|author=Nishad Majmudar|work=Rochester Democrat & Chronicle|date=1 September 2005|accessdate=28 May 2014}} 7. ^1 {{cite web|url=http://aumag.org/wordpress/2014/03/05/host-restrictive-factors/|title=The Deeper End of the Ocean: Host restrictive factors create research excitement|author1=Mariel Selbovitz|author2=David Miller|work=A&U: America's Aids Magazine|date=5 March 2014|issue=232|volume=23|page=52|accessdate=28 May 2014}} 8. ^{{cite journal | last = Salter | first = Jason D. | last2 =Morales | first2 =Guillermo A. | last3 =Smith | first3 =Harold C. | date= 11 August 2014 | title = Structural insights for HIV-1 therapeutic strategies targeting Vif. | journal=Trends in Biochemical Sciences |publisher=CellPress |pages=1–8 |doi= 10.1016/j.tibs.2014.07.001| pmid=25124760 | volume=39 | issue=9 | pmc=4511815}} 9. ^{{cite web|url=http://nydailyrecord.com/blog/2010/09/24/state-pension-fund-invests-in-rochester-venture/|title=State pension fund invests in Rochester venture|work=The Daily Record|date=24 September 2010|accessdate=1 June 2014}} 10. ^1 {{cite web|url=http://www.rochesterhomepage.net/story/dinapoli-tours-oyagen-touts-state-pension-fund/d/story/vjAERchZEEitncaBORblCQ|title=DiNapoli Tours OyaGen, Touts State Pension Fund|work=Rochester Homepage|date=16 September 2013|accessdate=1 June 2014}} 11. ^{{cite web|url=http://report.nih.gov/award/index.cfm?ot=&fy=2011&state=&ic=&fm=&orgid=10005030&distr=&rfa=&om=n&pid=&view=state|title=Awards summary for Fiscal Year|work=Research Portfolio Online Reporting Tools|date=2011|accessdate=1 June 2014}} 12. ^{{cite web|url=http://report.nih.gov/award/index.cfm?ot=&fy=2012&state=&ic=&fm=&orgid=10005030&distr=&rfa=&om=n&pid=&view=state|title=Awards summary for Fiscal Year|work=Research Portfolio Online Reporting Tools|date=2012|accessdate=1 June 2014}} 13. ^{{cite web|url=http://report.nih.gov/award/index.cfm?ot=&fy=2013&state=&ic=&fm=&orgid=10005030&distr=&rfa=&om=n&pid=&view=state|title=Awards summary for Fiscal Year|work=Research Portfolio Online Reporting Tools|date=2013|accessdate=1 June 2014}} Further reading
External links
2 : Companies based in Rochester, New York|HIV/AIDS research institutes |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。